Clinical trial · Interventional
Biophotonic Nanoparticle-enabled Laser Blood Test for Early Detection of Pancreatic Cancer
NCT07659639CI-TRIAL-00115461LASERBLOODrecruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
LASERBLOOD is based on a biophotonic technology that can be used to predict the development of Pancreatic Ductal Adenocarcinoma (PDAC) in particular categories of subjects at risk (e.g. persons with diabetes, obese people, patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\] or other cystic diseases of the pancreas, etc.) and at the same time offer the possibility of verifying the real effectiveness of the treatments to which affected patients are subjected.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Diabetes | — | UNRESOLVED | — |
| IPMN, Pancreatic | Pancreatic Intraductal Papillary Mucinous Neoplasm | ALIAS | 0.90 |
| PDAC - Pancreatic Ductal Adenocarcinoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Diagnostic procedures | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DIAGNOSTIC
- description
- Acquisition of biological material for bio-photonic technology analysis
- interventionNames
- Diagnostic Test: Diagnostic procedures
Primary outcomes (1)
- measure
- Diagnostic Accuracy of the Biophotonic Nanoparticle-Enabled Laser Blood Test (LASERBLOOD) for Detection of Pancreatic Ductal Adenocarcinoma (PDAC)
- timeFrame
- At baseline (time of enrollment), with reference standard diagnosis confirmed within 12 months
- description
- Area Under the Receiver Operating Characteristic Curve (AUC-ROC), with 95% confidence interval, of fluorescence lifetime fingerprints obtained by biophotonic laser analysis of nanoparticle-protein corona complexes in plasma, in discriminating subjects with histologically confirmed Pancreatic Ductal Adenocarcinoma (PDAC) from subjects without PDAC (including healthy controls and patients with Intraductal Papillary Mucinous Neoplasm \[IPMN\]). The reference standard is histopathological diagnosis (on surgical specimen or endoscopic ultrasound-guided fine-needle aspiration/biopsy \[EUS-FNA/B\]) for PDAC and IPMN, and radiological/clinical assessment for healthy controls.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
\*\*Inclusion criteria for patients with PDAC and IPMN:\*\* * No history of prior neoplastic diseases; * Adequate renal and hepatic function; * No hematologic disorders; * Age ≥ 18 years; * No active infections; * Written informed consent. \*\*Exclusion criteria:\*\* * Severe pre-existing medical conditions, such as serious illnesses or other medical conditions that could negatively affect study outcomes or pose a high risk to the patient's health; * Ongoing therapies that could interfere with the study or alter the results.
References
Publications (0)
Data not yet available
No reference posted for this study.